The Phytolacca americana-derived naturally occurring ribosome inhibitory protein pokeweed antiviral protein (PAP) is an N-glycosidase that catalytically removes a specific adenine residue from the stem loop of ribosomal RNA. We have employed molecular modeling studies using a novel model of PAP-RNA complexes and site-directed mutagenesis combined with bioassays to evaluate the importance of the residues at the catalytic site and a putative RNA binding active center cleft between the catalytic site and C-terminal domain for the enzymatic deadenylation of ribosomal RNA by PAP. substantially reduced the depurinating and ribosome inhibitory activity of PAP. These results provide unprecedented evidence that besides the active site residues of PAP, the conserved, charged, and polar side chains located at its active center cleft also play a critical role in the PAPmediated depurination of ribosomal RNA.
Pokeweed antiviral protein (PAP)
1 is a 29-kDa naturally occurring protein isolated from the leaves of the pokeweed plant, Phytolacca americana (1) (2) (3) . PAP belongs to a family of plant ribosome-inactivating proteins (RIPs) that catalytically depurinate ribosomal RNA (3, 4) . The enzymatic activity of PAP has been shown to be the specific cleavage of the glycosidic bond of a single adenine residue (A 4324 of the tetraloop sequence GAGA) that is located in the highly conserved sarcin/ ricin stem loop (4 -7) and is found in both eukaryotic rRNA (28 S) and in prokaryotic rRNA (23 S) . The ribosomes depurinated by PAP in this manner are unable to interact with elongation factors 1 and 2 (8, 9) , and thus the protein synthesis is irreversibly inhibited at the translocation step (7, 8) .
The x-ray structure of PAP has been determined previously and is composed of eight ␣ helices and a ␤ sheet consisting of six strands (15) (16) (17) . The refined crystal structure of PAP suggests that the protein can be divided into three domains: the Nterminal domain (residues 1-69, PAP numbering), the central domain (residues 70 -179), and the C-terminal domain (residues 180 -262). All of the highly conserved catalytic site residues (Tyr 72 , Tyr 123 , Glu 176 , and Arg 179 ) are located in the central domain. A deep cleft ("active center cleft") at the interface between the central and C-terminal domains forms the putative substrate-binding site (16) .
Structural studies involving complexes of PAP with various ligands (adenine, formycin, and pteoric acid) have helped clarify the nature of the substrate binding site of PAP (15, 17) and provided valuable information concerning its substrate specificity. However, these studies have largely been limited to single nucleotides or nucleotide analogs in the active site, and details of how PAP binds a larger RNA fragment of the ribosome remain unknown. Recent modeling studies of another member of the RIP family (ricin) have also been useful in suggesting binding modes of RNA fragments in the active site (18) . Based on structural, mutagenesis, and biochemical studies of several RIPs (ricin-A chain, trichosanthin, and momorcharin), it has been proposed that the amino acids Tyr 72 and Tyr 123 (PAP numbering) have the role of sandwiching the susceptible adenine ring of ribosomal RNA into the energetically favorable stacking conformation (19, 20) . Subsequently, the side chain of Arg 179 can protonate the N-3 atom of the adenine base, whereas Glu 176 stabilizes a positive oxocarbonium transition state (15, 20) . Huang et al. (21) have recently proposed that the N-7 atom of the adenine base can also be protonated by an acidic residue such as Asp 92 (PAP numbering) in trichosanthin and momorcharin.
We have recently reported the expression of biologically active recombinant PAP in Escherichia coli (22) . The biological activity of recombinant PAP was virtually identical to that of native PAP purified from the pokeweed plant (22) . The availability of recombinant PAP provides a unique opportunity for structure-activity relationship (SAR) analyses. Furthermore, we have refined the x-ray structure of PAP (17) and established a novel model of the PAP-RNA complex using the coordinates of PAP (Protein Data Bank access code 1qcg), PAP complexed with formycin 5Ј-monophosphate (Protein Data Bank access code 1pag), as well as the coordinates of the ribosomal RNA stem loop from the crystal structure of the 29-nucleotide RNA fragment (Protein Data Bank access code 430d) of rat 28 S ribosomal RNA, which contains the sarcin/ricin loop.
In the present SAR study, we employed molecular modeling studies using our model of PAP-RNA complexes and site-directed mutagenesis combined with bioassays to evaluate the importance of the residues at the catalytic site and a putative RNA binding active center cleft between the catalytic site and C-terminal domain for the enzymatic deadenylation of ribosomal RNA by PAP. As anticipated, alanine substitutions by site-directed mutagenesis of the PAP active site residues , and 90 FND 92 substantially reduced the depurinating and ribosome inhibitory activity of PAP. Our findings presented herein provide unprecedented experimental evidence that besides the catalytic site residues, the conserved charged and polar side chains located at the active site cleft of PAP also play a critical role in the catalytic removal of the adenine base from target ribosomal RNA substrates.
MATERIALS AND METHODS
Molecular Modeling-We first modeled the interaction of PAP with the single-stranded RNA heptamer GAGAGGA, which contains the target sequence for PAP. The initial position of GAGAGGA singlestranded RNA was built manually using RNA coordinates generated by InsightII (33) . The position of the adenine base in PAP active site pocket (Protein Data Bank access code 1QCI) (17) was used as a guide to properly position the second adenine in the modeled RNA heptamer. Major steric collisions with PAP were removed by manually adjusting the torsion angles of the phosphate backbone. The RNA heptamer was roughly positioned within the long concave region on the surface of PAP. This general position of the RNA heptamer was used as a starting point for subsequent docking trials. We created a definitive binding set of PAP residues in the active site pocket to move as a 3.5 Å shell around the manually docked RNA substrate during energy minimization. The number of final docking positions was set to 10, although finally only 2-4 promising positions were identified. The calculations used a consistent valence force field in the Discovery program and a Monte Carlo strategy in the Affinity program. Each energy-minimized final docking position of the ligand was evaluated using the interactive score function in the Ludi module. During RNA docking four torsion angles in phosphate backbone near the bound alanine were freed to increase the volume of conformational search. The final binding position of the RNA heptamer was determined based on the evaluation of favorable binding interactions using the Ludi score function. Ludi score included the contribution of the loss of translational and rotational entropy of the RNA fragment, number, and quality of hydrogen bonds and contributions from ionic and lipophilic interactions to the binding energy.
We next modeled the interaction of PAP with a 29-nucleotide RNA fragment of rat 28 S rRNA. The initial position of the ribosomal RNA stem loop in the PAP active site was built manually. This was done using the coordinates of PAP (Protein Data Bank access code 1qcg) (17) , PAP complexed with FMP (an adenosine analog, Protein Data Bank access code 1pag) (15) and the coordinates of the ribosomal RNA stem loop, which contains the sarcin/ricin loop, from the crystal structure of the 29-nucleotide RNA fragment (Protein Data Bank access code 430d) (23) . To place the RNA fragment in the PAP active site, the nucleotide A15 (analogous to A4324 in eukaryotic rRNA) was first removed from the coordinates of the RNA fragment. Because FMP binds the PAP active site in a conformation thought to be similar to that of the targeted adenine of the rRNA fragment, this position was used as a guide to place the resulting 28-nucleotide RNA fragment (residues 1-14, 16 -29) . The possible positions of this RNA fragment in the PAP active site were manually explored by allowing only rigid body movements under the following constraints: the 5Ј-phosphate group of G 16 should be within a bonding distance from the 3Ј-OH of FMP, and the 3Ј-OH of G 14 should be within a bonding distance from the 5Ј-phosphate group of FMP. Under such constraints, there was only one general position of the RNA structure that avoided major steric interference with PAP. Once the RNA fragment was positioned, the coordinates of the A 15 nucleotide were reinserted so that it matched the position of FMP. This general position of RNA in the active site of PAP was then used as a starting point for further modeling studies.
To refine this initial position and to explore other possible positions, the initial model was used to perform fixed docking using the Docking module in InsightII employing the CVFF forcefield (33) . The parameters used in this docking included searching for five unique structures: 1000 minimization steps for each structure, energy range of 10.0 kcal/ mol, maximum translation of the ligand of 3.0 Å, maximum rotation of the ligand of 10°, and an energy tolerance of 1500 kcal/mol. During the minimization steps of the docking procedure, only the stem loop residues 13-18 were allowed to be flexible, whereas the residues 1-12 and 19 -29 were held fixed. In addition, several distance and torsion restraints were applied to the 13-18 GC base pair to maintain this interaction.
Bacterial Strains and Construction of Mutants-Recombinant wildtype PAP (phosphate-buffered saline-PAP) was obtained by subcloning the PAP-I gene (amino acids 22-313) into the pBluescript SK
Ϫ expression vector (22) . Uracil-containing template of PAP was obtained by transforming E. coli CJ236 with the recombinant plasmid phosphatebuffered saline-PAP. The oligonucleotides used for site-directed mutagenesis were synthesized by Biosynthesis Inc. (Lewisville, TX). Sitedirected mutagenesis procedure was as described in the manufacturer's manual (Mutagene M13 in vitro mutagenesis kit; Bio-Rad). DNA sequencing was carried out by the method of Sanger et al. (24) following the manufacturer's instructions (U. S. Biochemical Corp.). Fine chemicals and restriction enzymes were purchased from Roche Molecular Biochemicals.
Expression and Purification of Mutants-Wild-type and mutant recombinant(r) PAP proteins were expressed in E. coli MV1190 as inclusion bodies, isolated, solubilized, and refolded as described previously (22) . The refolded proteins were analyzed by SDS-12% polyacrylamide gel electrophoresis (PAGE). Protein concentrations were determined from the gel using bovine serum albumin as a standard.
Immunoblot Analysis of rPAP Mutants-The protein samples were resolved on a SDS-12% PAGE and transferred onto a polyvinylidene difluoride membrane (Bio-Rad) using the Bio-Rad trans-blot apparatus, as described previously (22) . The membrane was immunoblotted using rabbit anti-PAP serum (1:2000 dilution) and horseradish peroxidaseconjugated goat anti-rabbit IgG (Sigma) as the primary and secondary antibodies, respectively. The blot was developed using 3,3Ј-diaminobenzidine (Sigma) as the colorimetric indicator for peroxidase activity.
Aniline Cleavage Assays of Ribosomal RNA Depurination-5 g of E. coli 16 S and 23 S rRNA (Roche Molecular Biochemicals) or 30 g of total ribosome prepared from the rabbit reticulocyte-rich whole blood (25) were incubated with either 5 or 25 g of wild-type or mutant rPAP proteins in 50 l (final volume) of binding buffer (25 mM Tris⅐HCl, pH 7.8, 10 mM KCl, 5 mM MgCl 2 , 2% glycerol) at 37°C for 1 h. The RNA was extracted with phenol:chloroform (24:24), precipitated with ethanol, and treated with 20 l of 1 M aniline acetate (pH 4.5) for 30 min on ice. The RNA was precipitated with ethanol, electrophoresed in a 6% urea/ polyacrylamide gel, and stained with ethidium bromide as described previously (22) .
Adenine Release Assays-The release of adenine from E. coli ribosomal RNA (Roche Molecular Biochemicals) was measured using HPLC (Hewlett Packard, Palo Alto, CA) equipped with a diode array detector and a ChemStation software program for data analysis (14). E. coli ribosomal RNA (2 g) was incubated with 5.0 M of wild-type or mutant rPAP proteins for 1 h at 37°C in 50 l of binding buffer (25 mM Tris⅐HCl, pH 7.8, 10 mM KCl, 5 mM MgCl 2 , 2% glycerol). The reaction was stopped by adding 100 l of HPLC running buffer (50 mM NH 4 C 2 H 3 O 2 , 5% methanol, pH 5.0), and 100 l of the sample was injected automatically into a reverse-phase Lichrospher 100RP-18E analytical column (Hawlett-Pakard, 5-mm particle size, 250 ϫ 4 mm) that was equilibrated with HPLC running buffer. The detector wavelength was set at 260 nm, and the sample was eluted under isocratic conditions at a flow rate of 1.0 ml/min as described before (14). Controls included (a) samples containing untreated ribosomal RNA and (b) samples without ribosomal RNA. The adenine standard was purchased from Sigma. A calibration curve was generated to establish the linear relationship between the absolute peak area and the concentrations of adenine in the tested samples. Adenine at final concentrations of 0.1, 0.5, 1.0, 2.5, and 5.0 M (5, 25, 50, 125, and 250 pmol/50 ml, respectively) was injected into the HPLC system for analysis, and the calibration curve was generated by plotting the absolute peak area against the concentrations of adenine as described previously (14). Unweighted linear regression analysis of the calibration curve was performed by using the CA-Cricket graph III computer program (Computer Association, Inc., Islandia, NY). Intra-assay and inter-assay accuracy and precisions were evaluated as described previously (14). Under the described chromatographic conditions, the retention time for adenine was 9.7 min, and adenine was eluted without an interference peak from the blank controls (data not shown). The lowest limit of detection for adenine was 2.5 pmol at a signal to noise ratio of Ϸ3. The intra-and inter-assay coefficients of variation were less than 4%. The overall intra-and inter-assay accuracies of this method were 98.7 Ϯ 1.7% (n ϭ 6) and 95.7 Ϯ 3.0% (n ϭ 6), respectively.
Cell-free Translation Assays-Protein synthesis was assayed in a cell-free system using nuclease-treated rabbit reticulocyte lysates (Promega, Madison, WI) and luciferase mRNA, as described previously (22) . In this assay, luciferase mRNA was translated in the presence or absence of increasing concentrations of wild-type or mutant rPAP proteins. Luciferase mRNA encodes for a monomeric protein of 61 kDa on SDS-PAGE. In brief, varying amounts (0.01-12,000 ng/ml) of wild-type or mutant rPAP proteins were added to the translation mixture (10 l rabbit reticulocyte lysate; 0.5 l of 1.0 mM methionine-free amino acids mixture; and 1.0 l of [ 35 S]methionine, 10 mCi/ml) to a final volume of 19 l and incubated for 15 min at room temperature. Protein synthesis was initiated by adding 0.12 g of luciferase mRNA in a 1.0-l volume, and the incubation was continued for 2 h at 30°C. Translation was stopped by the addition of 5% trichloroacetic acid, and the precipitated polypeptides were collected on Whatman GF/C glass microfiber filters. The incorporation of 35 S was determined by counting the radioactivity on the filters using a liquid scintillation counter (Beckman LS 6000SC) as described previously (22) . The IC 50 (50% inhibitory concentration) values were calculated by nonlinear regression analysis (Prism-2 Graph Pad software, San Diego, CA) using the average values of three independent experiments. The cpm values in control sample with all the reagents added except the test sample ranged from 3 to 4 ϫ 10 7 cpm/ml and were considered as 100% incorporation when determining the percentage of control protein synthesis values for samples treated with test materials.
RESULTS AND DISCUSSION
Modeling Studies of the Catalytic Active Site and RNA-binding Residues of PAP-Our first model of PAP-RNA heptamer complex (i.e. PAP-GAGAGGA complex) indicated that the target RNA heptamer can bind very strongly to PAP via multiple interactions along the concave cleft region (Fig. 1) and G 5 ) of the bound adenine (A 4 ) do not have any specific interactions with PAP, whereas the other ribonucleotides interact with the active site cleft residues. These interactions help to properly position the adenine base in the PAP active site so that it can be cleaved with high efficiency.
Our second more advanced model of PAP-RNA complex involved an RNA stem loop fragment (29-nucleotide, 5Ј-GGGUGCUCAGUACGAGAGGAACCGCACCC-3Ј) docked into the active site of PAP as shown in Fig. 2 . This orientation allows the purine ring of adenine, at the position that corresponds to 15 and is proposed to stabilize the positive oxocarbonium ion that develops on the ribose group in the transition state (15, 26).
Another active site residue Arg 179 also shows a similar conformation where it is in a position to protonate N 3 of the adenine ring. Thus, the overall conformation of the PAP active site residues of our model is similar to those observed previously (18) , as shown in Fig. 2 .
The base stacking pattern of the model is also interesting to (Fig. 3) . According to our model, Asp 92 interacts with the base of G 16 and may therefore contribute to the binding of PAP to the tetra-loop structure of RNA (Fig. 3) . Our model also suggests that the side chain of Trp 208 can engage in a hydrophobic interaction with the ribose of G 16 and the amide backbone of Trp 208 can form hydrogen bonds with the phosphate backbone of G 16 . Therefore, mutations involving Trp 208 could result in local conformational change at the catalytic site of the PAP and disrupt these stabilizing interactions with G 16 . Our models indicate that the above interactions are important for binding, orientation, and stabilization of the RNA substrate, and their mutation could therefore lead to significant loss of catalytic activity. Obviously the removal of positively charged residues will diminish the strength of binding to the negatively charged phosphate backbone of RNA and subsequently reduce the activity PAP. Besides, Asn 70 forms a hydrogen bond with the catalytic site residue Arg 179 , and ala- nine mutation of this residue would therefore likely affect the enzymatic activity of PAP.
Construction and Expression of PAP Mutants-Recombinant PAP mutants with alanine substitutions of the conserved catalytic site and active center cleft residues were constructed using site-directed mutagenesis techniques. Alanine substitutions were considered because the replacement of side chains with alanine would be least disruptive to the overall structure (27) . Also, alanine does not impose new hydrogen bonding, sterically bulky, or unusually hydrophobic side chains (27) . An amino acid alignment of PAP residues, selected for mutagenesis, with those of PAP-II, PAP-S, and ricin-A chain is shown in Fig. 4 . The active site residues selected for mutagenesis are highly conserved among the various RIPs identified to date (Fig. 4A) . The residues outside the active site chosen for mutagenesis are highly conserved among the PAP isoforms, but they are different from those in ricin-A chain (Fig. 4C) . The positions, chemical nature, and secondary structural elements of the amino acids substituted with alanine are indicated in Table I .
Thirteen point mutants of recombinant PAP (Table I) , containing single, double, or triple alanine substitutions, were constructed and expressed in the E. coli strain, MV1190, as inclusion bodies. The inclusion bodies were purified, solubilized, refolded, and analyzed by SDS-PAGE (Fig. 5A) . All of the mutant proteins were expressed in yields comparable to that of the wild-type PAP (Fig. 5A) . The solubilized and refolded mutants displayed a 33-kDa major protein on SDS-PAGE, were highly reactive to the anti-PAP serum and were stable under our solubilization and refolding conditions (Fig. 5B) . Fig. 1 ). Based on our modeling studies we did not expect these mutants to have substantially reduced activity. The experimentally determined IC 50 values from cell-free translation assays confirmed that the ribosome inhibitory activity of FLP-1, FLP-6, FLP-8, and FLP-10 proteins (IC 50 ϭ
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FIG. 4. Structural alignment of selected primary sequence of PAP-I with PAP-II, PAP-S and Ricin-A.
Numbering is relative to the initiation codon. A, comparison of the residues that were conserved among the RIPs. B, stereoview of the active site residues along with the adenine residue (A15) of RNA. The PAP residues thought to be involved in the catalytic mechanism (Y72, V73, Y123, E176, and R179) are also shown. The figure was produced using MOLSCRIPT (29) . C, comparison of the amino acids that are highly conserved among the PAP isoforms but not ricin-A chain. The conserved residues are in bold type. The residues that were mutated in this study are underlined in the PAP-I sequence.
5.9 Ϯ 1.0, 49 Ϯ 3.0, 6.7 Ϯ 1.0, and 6.8 Ϯ 0.9 ng/ml, respectively) were comparable with that of the wild type (IC 50 ϭ 5.7 Ϯ 1.0 ng/ml; Fig. 6A and Table I ). The data from adenine release assays and aniline cleavage assays were in accordance with the translation inhibition data.
The Fig. 1) . Alanine substitutions at these locations were expected to affect the orientation of the substrate adenine in the active site and subsequent enzymatic cleavage of the glycosidic bond. As predicted from our modeling studies, these mutants were enzymatically inactive ( Fig. 6B and Table I ). At a 5 M concentration, wild-type PAP released 396 Ϯ 15 pmol of adenine/g of ribosomal RNA (Table I) . By comparison, the catalytic site mutants, FLP-5, FLP-9, FLP-11, FLP-12, and FLP-13 released 9 Ϯ 2, 12 Ϯ 3, 7 Ϯ 2, 14 Ϯ 7, and 4 Ϯ 2 pmol of adenine/g of rRNA, respectively. Substitution of the catalytic active site residues 71 LY 72 (FLP-5) and 122 RY 123 (FLP-9), Glu 176 (FLP-11) and Trp 208 (FLP-13) have resulted in nearly complete loss (Ͼ1700-fold less active) of ribosomal depurination activity, as we expected. Arg 179 (active site residue), however, apparently plays a less important role in catalytic deadenylation than the other active site residues (only 385-fold less active than the wild type). Fig. 1 ). All of these mutated residues are involved in a complex network of interactions pivotal for the proper orientation of the substrate RNA. In addition, Asn 70 (FLP-4) forms a hydrogen bond with the catalytic residue Arg 179 , and alanine substitution might lead to a functionally unfavorable conformation of the Arg 179 side chain (Fig. 7) . Notably, mutations at the active center cleft have markedly diminished (23-, 33-191-, and 352-fold less active, respectively) the enzymatic activity of PAP ( Fig. 6C and Table I ). As shown in Fig. 6 , the inhibition curves shifted to the right, consistent with a significant decrease in enzymatic activity. The bioassays were carried out using at least four different preparations of wild-type and mutant rPAP and yielded comparable results. Substitution of 48 KY 49 (FLP-2) at the far end of the cleft had a less pronounced effect on the catalytic activity (23-fold less active) than the substitution of the residues 67 RR 68 , 69 NN 70 , and 90 FND 92 that are located closer to the catalytic site (Table I ). The adenine release assays were also consistent with the protein synthesis inhibition assay results (Table I) .
We next examined whether there was deadenylation of ribosomal RNA (rabbit) by the catalytic site mutants or active center cleft mutants. The rabbit rRNA depurination was determined by treating the ribosomes with wild-type or mutant proteins and subsequent purification of the rRNA and cleavage with aniline. Because aniline cleaves the sugar-phosphate backbone of RNA at depurination sites, the release of fragments from aniline-treated RNA is indicative of depurination. Our results indicated that neither the catalytic site mutants nor the active site cleft mutants have deadenylated the rRNA (Fig. 8A) .
The ribosomal RNA depurination activity was also determined by treatment of E. coli 16 S and 23 S ribosomal RNA with wild-type and mutant proteins and subsequent cleavage of the treated RNA with aniline. Treatment of the naked rRNA (2 g) with 2.5 g of either the wild-type or the enzymatically active mutant proteins (FLP-1, FPL-8, and FLP-10) has released an RNA fragment of Ϸ240 nucleotides (Fig. 8B) , whereas the less active mutants, FLP-2 and FLP-3, required a 10-fold higher amount of protein (25 g ) to release the 240-nucleotide RNA fragment (Fig. 8C) . On the other hand, the mutants that substantially reduced the deadenylation activity (FLP-5, FLP-7, FLP-9, FLP-11, and FLP-13) did not release the fragment even at 25 g/ml concentration of the mutant proteins (Fig. 8D) . These results are in agreement with the data obtained from adenine release assays and protein synthesis inhibition assays.
In summary, we employed molecular modeling studies using our model of PAP-RNA complexes and site-directed mutagenesis combined with bioassays to evaluate the importance of the residues at the catalytic site and a putative RNA binding active center cleft between the catalytic site and C-terminal domain for the enzymatic deadenylation of ribosomal RNA by PAP. Our findings presented herein provide unprecedented experimental evidence that in addition to the catalytic site residues, the conserved charged and polar side chains located at the active site cleft of PAP also play a critical role in the catalytic removal of the adenine base from target ribosomal RNA substrates.
